The reason Biotech ETFs are reaching new heights

Lately, the biotech space has witnessed very sturdy M&A activity. The trend is predicted to continue following the fact that large pharmaceutical firms are hoping to gain an advantage in the continually competitive market for treatments of cancer. 

M&A activity has come up to a record $342 billion so far in 2019. This indicates the finest year by total deal value ever since the start of tracking in the 1990s, as stated b....